From the Journals

Consider cutaneous endometriosis in women with umbilical lesions


 

FROM THE INTERNATIONAL JOURNAL OF WOMEN’S DERMATOLOGY

Cutaneous endometriosis should be considered as a diagnosis when umbilical lesions are present, especially if there is a history of pain flares during menses, according to Liza Raffi of the University of Southern California, Los Angeles, and associates.

KatarzynaBialasiewicz/Thinkstock

The report, published in the International Journal of Women’s Dermatology, detailed a case of a woman aged 41 years who presented with a 5-month history of a painful firm subcutaneous nodule in the umbilicus and flares of pain during menstrual periods. Her past history indicated a missed miscarriage (removed by dilation and curettage) and laparoscopic left salpingectomy for a ruptured ectopic pregnancy.

At presentation, the woman reported undergoing fertility treatments including subcutaneous injections of follitropin beta and choriogonadotropin alfa.

Because of the patient’s history of salpingectomy and painful menstrual periods, her physicians suspected cutaneous endometriosis. An ultrasound was performed to rule out fistula, and then a punch biopsy of the nodule was performed. The biopsy showed endometrial glands with encompassing fibrotic stroma, which was consistent with cutaneous endometriosis, likely transplanted during the laparoscopic port site entry during salpingectomy.

The patient chose to undergo surgery for excision of the nodule, declining hormonal therapy because she was undergoing fertility treatment.

“The differential diagnosis of umbilical lesions with similar presentation includes keloid, dermatofibroma, dermatofibrosarcoma protuberans, and cutaneous metastasis of cancer,” the investigators wrote. “Ultimately, patients should be referred to obstetrics & gynecology if they describe classic symptoms including pain with menses, dyspareunia, and infertility and wish to explore diagnostic and therapeutic options.”

Ms. Raffi and associates reported they had no conflicts of interest. There was no external funding.

SOURCE: Raffi L et al. Int J Womens Dermatol. 2019 Jul 2. doi: 10.1016/j.ijwd.2019.06.025.

Recommended Reading

By the numbers: Readmissions for skin conditions
MDedge Dermatology
Molecular profiling shows promise for treating unusual skin rashes
MDedge Dermatology
Major increase in hidradenitis suppurativa cases anticipated
MDedge Dermatology
Review clarifies depression, anxiety risk among hidradenitis suppurativa patients
MDedge Dermatology
AAD issues position statement addressing sexual, gender minority health
MDedge Dermatology
Cumulative smoking affects skin manifestations of SLE
MDedge Dermatology
Antibody hierarchy may drive development of SLE vs. antiphospholipid syndrome
MDedge Dermatology
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse events
MDedge Dermatology
Antimalarial may be effective, safe for erosive oral lichen planus
MDedge Dermatology
Bullous disorders linked to frequent interruption of immune checkpoint inhibitor treatment
MDedge Dermatology